A Double-Blind, Placebo-Controlled, Randomized Phase III Study of Ipatasertib in Combination With Paclitaxel as a Treatment for Patients With PIK3CA/AKT1/PTEN-Altered, Locally Advanced or Metastatic, Triple-Negative Breast Cancer or Hormone Receptor-Positive, HER2-Negative Breast Cancer

Trial Profile

A Double-Blind, Placebo-Controlled, Randomized Phase III Study of Ipatasertib in Combination With Paclitaxel as a Treatment for Patients With PIK3CA/AKT1/PTEN-Altered, Locally Advanced or Metastatic, Triple-Negative Breast Cancer or Hormone Receptor-Positive, HER2-Negative Breast Cancer

Recruiting
Phase of Trial: Phase II/III

Latest Information Update: 11 Aug 2018

At a glance

  • Drugs Ipatasertib (Primary) ; Paclitaxel (Primary)
  • Indications Adenocarcinoma; Advanced breast cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms IPATunity130
  • Sponsors Roche; Roche Farma
  • Most Recent Events

    • 21 Jun 2018 Planned End Date changed from 13 Mar 2021 to 31 Mar 2021.
    • 21 Jun 2018 Planned primary completion date changed from 13 Mar 2021 to 31 Mar 2021.
    • 05 Jun 2018 Trial design presented at the 54th Annual Meeting of the American Society of Clinical Oncology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top